For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
The LANCE® Ultra Human ErbB2 (HER2) Detection Kit is designed for detection and quantitation of human ErbB2 in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
Human epidermal growth factor receptor 2 (ERBB2, NEU, or HER2) is a type I membrane glycoprotein that is a member of the ERBB family of tyrosine kinase receptors. It serves as a receptor for the epidermal growth factor (EGF) family of growth factors. HER2 is widely expressed in epithelial cells and has also been found to be over-expressed in a large number of breast carcinomas. It is an orphan receptor with no known ligand, as it acts as a heterodimer with other members of the EGF receptors family. HER2 appears to play roles in development, cancer, communication at the neuromuscular junction, and regulation of cell growth and differentiation. HER2 can be shed from the cell surface as a soluble protein (sHER2) via proteolytic cleavage by an unidentified protease. sHER2 seems to be an important serum biomarker in certain types of cancer.
| Assay Target | ErbB2 |
|---|---|
| Assay Target Class | Protein |
| Automation Compatible | Yes |
| Detection Method | Time-Resolved Fluorescence (TRF), TR-FRET |
| Experimental Type | In vitro |
| Product Brand Name | LANCE Ultra |
| Shipping Condition | Blue Ice |
| Therapeutic Area | Cancer |
| Unit Size | 10,000 Assay Points |
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.
